Harbor Investment Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

Harbor Investment Advisory’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-999	Closed	-$54K	–	1365
2022 Q3	$54K	Hold	999	–	–	0.01%	662
2022 Q2	$56K	Hold	999	–	–	0.01%	679
2022 Q1	$70K	Buy	999 +154	+18%	+$11.2K	0.01%	642
2021 Q4	$81K	Hold	845	–	–	0.01%	593
2021 Q3	$73K	Hold	845	–	–	0.01%	608
2021 Q2	$69K	Hold	845	–	–	0.01%	612
2021 Q1	$80K	Sell	845 -165	-16%	-$15.6K	0.01%	541
2020 Q4	$63K	Buy	1,010 +271	+37%	+$15.4K	0.01%	576
2020 Q3	$44K	Buy	739 +390	+112%	+$26.6K	0.01%	529
2020 Q2	$24K	Buy	349 +41	+13%	+$2.6K	0.01%	592
2020 Q1	$14K	Buy	+308	New	+$17.5K	﹤0.01%	658

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbor Investment Advisory's LGND Position: Q4 2022 in Review

Harbor Investment Advisory sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 999 shares — an estimated $54K sold.

Harbor Investment Advisory first reported a position in LGND in Q1 2020 and held it in 11 quarters. The position peaked at $81K in Q4 2021. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

Harbor Investment Advisory reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Harbor Investment Advisory sold 999 Ligand Pharmaceuticals shares in Q4 2022, an estimated $54K.
Harbor Investment Advisory first reported a position in Ligand Pharmaceuticals in Q1 2020 and held it in 11 quarters.
Harbor Investment Advisory's Ligand Pharmaceuticals position peaked at $81K in Q4 2021.
198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Harbor Investment Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.